Posted by Michael Wonder on 24 Feb 2022
EMA recommends approval of Spikevax for children aged 6 to 11
24 February 2022 - EMA’s CHMP has recommended granting an extension of indication for the COVID-19 vaccine Spikevax to include use in children aged 6 to 11.
The vaccine, developed by Moderna, is already approved for use in adults and children aged 12 and above.
